| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
As a synthetic intermediate, N2-(((9H-Fluoren-9-yl)methoxy)carbonyl)-N6-((5-(dimethylamino)naphthalen-1-yl)sulfonyl)-L-lysine has no specific biological target. Its role is to provide dansyl-labeled lysine residues in peptide chains. The Fmoc protecting group enables standard Fmoc solid-phase peptide synthesis (SPPS) workflows. The dansyl fluorophore provides strong fluorescence that can be used to monitor peptide binding, cellular uptake, and protein interactions. The compound does not interact with enzymes or receptors in pharmacological assays in its protected form. Its "target" is the peptide coupling reaction, where it acts as a protected amino acid donor. This compound is particularly valuable for synthesizing fluorescently labeled peptides for imaging and binding studies.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The in vitro activity of N2-(((9H-Fluoren-9-yl)methoxy)carbonyl)-N6-((5-(dimethylamino)naphthalen-1-yl)sulfonyl)-L-lysine is measured by coupling efficiency in solid-phase peptide synthesis (SPPS). Typically, it is coupled to resin-bound amine using standard Fmoc-SPPS conditions: deprotection of the resin-bound Fmoc group with 20% piperidine in DMF, followed by coupling with the compound (typically 3-5 equivalents) using coupling reagents such as HATU, HBTU, or DIC with HOBt, and DIEA as base. Coupling efficiency is monitored by the Kaiser test or by quantitative HPLC. Purity is typically ≥98%. No inherent biological activity is observed as the compound is a protected amino acid derivative. The dansyl fluorophore provides fluorescence for detection and quantification. |
| ln Vivo |
In vivo activity is not applicable for N2-(((9H-Fluoren-9-yl)methoxy)carbonyl)-N6-((5-(dimethylamino)naphthalen-1-yl)sulfonyl)-L-lysine. The compound is not used in animals and is a research chemical for laboratory synthesis only.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cellular) experimental workflow for N2-(((9H-Fluoren-9-yl)methoxy)carbonyl)-N6-((5-(dimethylamino)naphthalen-1-yl)sulfonyl)-L-lysine involves standard Fmoc solid-phase peptide synthesis procedures. Standard SPPS cycle: deprotect Fmoc with 20% piperidine in DMF (typically 2 × 5-10 minutes), wash with DMF, couple the compound (3 equiv.) with HATU (2.9 equiv.) and DIEA (6 equiv.) for 1-2 hours, wash, repeat. After complete assembly of the peptide sequence, the peptide is cleaved from the resin and deprotected using a cleavage cocktail containing TFA, TIS, and water (typically 95:2.5:2.5) for 2-4 hours. The crude peptide is analyzed by HPLC-MS. The compound's LogP is 7.208, indicating high lipophilicity.
|
| Cell Assay |
In vitro cell-based experimental workflows may involve using the final dansyl-labeled peptides for fluorescence-based assays. Cells are cultured in appropriate medium, treated with the fluorescent peptide, and analyzed by fluorescence microscopy or flow cytometry. The dansyl fluorophore allows for visualization of peptide uptake and localization.
|
| Animal Protocol |
In vivo animal experiments are not applicable for N2-(((9H-Fluoren-9-yl)methoxy)carbonyl)-N6-((5-(dimethylamino)naphthalen-1-yl)sulfonyl)-L-lysine. The compound is stored as a powder at -20°C or 4°C.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties have not been characterized. The compound is not a drug. The compound is stable under recommended storage conditions: powder at -20°C for up to 3 years or at 4°C for up to 2 years; in solvent at -80°C for up to 1 month.
|
| Toxicity/Toxicokinetics |
The toxicological data are limited. Standard laboratory safety practices should be followed. The compound is intended for research use only.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
N2-(((9H-Fluoren-9-yl)methoxy)carbonyl)-N6-((5-(dimethylamino)naphthalen-1-yl)sulfonyl)-L-lysine is a fluorescently labeled lysine derivative featuring a dansyl fluorophore. The dansyl group provides strong fluorescence for studying protein-protein interactions and cellular localization. The compound is not a drug and has no clinical trials or approvals. The compound is for research use only.
|
| Molecular Formula |
C33H35N3O6S
|
|---|---|
| Molecular Weight |
601.71
|
| Exact Mass |
601.225
|
| CAS # |
118584-90-0
|
| PubChem CID |
51340512
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
7.208
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
43
|
| Complexity |
1030
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCCC[C@@H](C(=O)O)NC(=O)OCC3C4=CC=CC=C4C5=CC=CC=C35
|
| InChi Key |
SLBNIPMLSUPCFW-LJAQVGFWSA-N
|
| InChi Code |
InChI=1S/C33H35N3O6S/c1-36(2)30-18-9-16-27-26(30)15-10-19-31(27)43(40,41)34-20-8-7-17-29(32(37)38)35-33(39)42-21-28-24-13-5-3-11-22(24)23-12-4-6-14-25(23)28/h3-6,9-16,18-19,28-29,34H,7-8,17,20-21H2,1-2H3,(H,35,39)(H,37,38)/t29-/m0/s1
|
| Chemical Name |
(2S)-6-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6619 mL | 8.3097 mL | 16.6193 mL | |
| 5 mM | 0.3324 mL | 1.6619 mL | 3.3239 mL | |
| 10 mM | 0.1662 mL | 0.8310 mL | 1.6619 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
